Standardization and individualization of PRRT: Bodei and colleagues focus on standardization of peptide receptor radionuclide therapy as a starting point for redefining the paradigm from a one-size-fits-all approach to personalized treatment. ***Page 1753***

PET/CT in GEP neuroendocrine neoplasms: Schillaci provides an overview of the current and potential roles of PET/CT in guiding patient management in gastroenteropancreatic neuroendocrine neoplasms and previews an article on this topic in this issue of *JNM*. ***Page 1757***

^{124}I PET and response in DTC: Jentzen and colleagues analyze ^{124}I PET/CT imaging data from patients with differentiated thyroid cancer to assess relationships between absorbed radiation dose to lesions and response after radioiodine therapy. ***Page 1759***

^{18}F-FDG accumulation and LDHA expression: Zhou and colleagues investigate the relationship between lactate dehydrogenase A and tracer accumulation on ^{18}F-FDG PET imaging in patients with lung adenocarcinomas. ***Page 1766***

Parametric methods for ^{18}F-FAZA: Verwer and colleagues determine the validity of parametric methods for quantification of this hypoxia-specific PET tracer with potential for, among other applications, early response monitoring and radiation therapy dose painting. ***Page 1772***

D-^{18}F-FMT clinical results: Burger and colleagues demonstrate tumor detection with PET using this novel radiolabeled tyrosine derivative in patients with non–small cell lung and head and neck squamous cell cancers and compare results with those from ^{18}F-FDG. ***Page 1778***

PET and NETs: Bahri and colleague assess the long-term prognostic utility of ^{18}F-FDG PET for patients with metastatic gastroenteropancreatic neuroendocrine tumors. ***Page 1786***

^{99m}Tc-PSMA inhibitors for prostate cancer: Vallabhajosula and colleagues offer first human data on a novel ^{99m}Tc-labeled small-molecule prostate-specific membrane antigen inhibitor that binds with high affinity to PSMA-positive tumor cells in vitro and localizes in prostate cancer xenografts. ***Page 1791***

Sentinel nodes in ovarian cancer: Kleppe and colleagues explore the feasibility of the sentinel node technique in ovarian cancer with tracer injection into the ovarian ligaments and evaluate the safety of the procedure for health care workers. ***Page 1799***

Brain glucose metabolism and neurocognition in ALL: Krull and colleagues examine associations between regional brain metabolism, as measured by ^{18}F-FDG PET, and neurocognitive outcomes in adult survivors of childhood acute lymphoblastic leukemia treated with cranial radiation. ***Page 1805***

PET tracer choice in GEPNETs: Has Simsek and colleagues compare ^{68}Ga-DOTATATE and ^{18}F-FDG PET/CT in gastroenteropancreatic neuroendocrine tumors and look at complementarities between PET/CT results and histopathologic findings in therapy management, particularly in intermediate-grade patients. ***Page 1811***

^{11}C-donepezil PET: Gjerløff and colleagues evaluate the utility of ^{11}C-donepezil for PET imaging of acetylcholinesterase densities in peripheral organs, including the salivary glands, heart, stomach, intestine, pancreas, liver, and spleen. ***Page 1818***

MR AC for brain PET/MR: Izquierdo-Garcia and colleagues describe a new approach for head MR-based attenuation correction with statistical parametric mapping, combining segmentation- and atlas-based features to generate attenuation maps for integrated PET/MR imaging. ***Page 1825***

Imaging of ischemic stroke: Heiss presents a broad educational overview of clinical applications of radionuclide imaging in the management of stroke, including both limitations and promising future perspectives. ***Page 1831***

^{188}Re-labeled Affibody molecule: Altai and colleagues assess the feasibility of ^{188}Re-$Z_{HER2:V2}$ as a potential candidate agent for radionuclide therapy of human epidermal growth factor receptor type 2–expressing tumors. ***Page 1842***

Monitoring response with ^{111}In-RGD$_2$: Terry and colleagues evaluate in animal studies the potential of this RGD-based imaging tracer, which allows specific imaging of integrin $\alpha_v\beta_3$ expression, to monitor early responses to antiangiogenic or radiation therapy. ***Page 1849***

LLP2A conjugates for melanoma imaging: Beaino and Anderson assess in a murine model 2 radiolabeled conjugates of a high-affinity integrin $\alpha_4\beta_1$ peptidomimetic ligand for PET/CT imaging in subcutaneous and metastatic melanoma tumors. ***Page 1856***

^{188}Re-PEGylated liposomes in NSCLC: Lin and colleagues investigate the biodistribution, pharmacokinetics, and therapeutic efficacy of novel nanoradiopharmaceuticals on non–small cell lung cancer using a xenograft lung tumor model and reporter gene imaging techniques. ***Page 1864***

Lung metabolism in experimental ARDS: Prost and colleagues ask how local ^{18}F-FDG phosphorylation rate and volume of distribution are related to initial regional inflammatory response during early acute lung injury and to specific mechanisms of injury. ***Page 1871***

Monitoring bevacizumab therapy: Rylova and colleagues use histologic techniques and molecular imaging with PET and ^{68}Ga-NODAGA-c (RGDfK) to follow bevacizumab treatment of squamous cell carcinoma xenografts to determine whether $\alpha_v\beta_3$ integrin imaging can monitor tumor angiogenesis. ***Page 1878***

(−)-^{18}F-flubatine dosimetry: Sattler and colleagues detail organ doses and effective doses of this promising PET tracer for neuroimaging of nicotinic α4β2 acetylcholine receptors in animals and human volunteers. ***Page 1885***

LED device for PIT: de Boer and colleagues describe the development of a light-emitting diode photoimmunotherapy device, including validation of feasibility, applicability, safety, and consistency of the system for cancer treatment. ***Page 1893***

Microscopic optical and nuclear validation: Inoue and colleagues develop a fiducial marker simultaneously compatible with 2-color near-infrared fluorescence autoradiography and conventional hematoxylin–eosin histology to explore the molecular and cellular bases for radioscintigraphic signals in macroscopic in vivo imaging. ***Page 1899***

Cerenkov luminescence imaging of β-emitters: Carpenter and colleagues investigate improvements in sensitivity of Cerenkov luminescence endoscopy with a β^- radiotracer providing both higher β-particle energy and lower γ noise in the imaging optics. ***Page 1905***

Separation of ^{99m}Tc from molybdenum: Bénard and colleagues describe a simple kit-based approach for purification of pertechnetate ($^{99m}TcO_4^-$) from solutions with high MoO_4^{2-} content. ***Page 1910***